AIM ImmunoTech Inc. (AIM) Completes Dosing; Phase 2 Results Expected Q1 2027
AIM ImmunoTech completed dosing in its Phase 2 DURIPANC study. The company expects topline clinical benefit results in Q1 2027 and survival analyses in Q3 2027, according to its press release.
How this was made

The 30-second read
Why it matters
The completion of dosing is a standard trial milestone; price movement will depend on the forthcoming efficacy and survival data.
Market read
The news is a modest update for AIM shareholders; broader market impact is limited.
What to watch
Potential partnership or licensing discussions could arise after data readout, affecting valuation.
Background
AIM ImmunoTech is a Nasdaq‑listed biotech developing Ampligen for immunotherapy. The Phase 2 DURIPANC study has now completed dosing.
Ticker impact
AIM ImmunoTech announced completion of Phase 2 dosing, a new milestone for its Ampligen trial.
likely modest pressure as the market prices in the pending data readout
No efficacy results are available yet, so the news does not provide a clear upside or downside.
Market effects
May keep biotech sector attention on upcoming trial readouts but no immediate sector shift.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact; only relevant to investors tracking immunotherapy pipelines.
Counterpoint
Some traders may short on the basis that the lack of data could lead to disappointment.
Key entities
- companyAIM ImmunoTech Inc.
Biotech firm developing Ampligen.